Armour Thyroid Cognitive Function Impact: What the Evidence Actually Shows

Why T3 Matters for the Brain

The thyroid gland secretes roughly 80% T4 and 20% T3 [1]. T4 is a prohormone. Neurons, astrocytes, and oligodendrocytes convert T4 to the active form T3 via deiodinase type 2 (DIO2), but this conversion is incomplete and regionally variable in the brain [2]. Patients who carry a common DIO2 polymorphism (Thr92Ala, present in approximately 12-16% of the general population) show reduced intracellular T3 production even when serum T4 is normal [3].

Levothyroxine (synthetic T4 only) does not directly supply T3. Armour Thyroid supplies both, at a fixed 4.22:1 T4-to-T3 ratio by weight.

T3 Receptor Distribution in Cognitive Regions

Thyroid hormone receptors, specifically TRα1 and TRβ1, are expressed at high density in the hippocampus, prefrontal cortex, and amygdala, regions governing memory encoding, executive function, and emotional regulation [4]. Animal models show that T3 deprivation in these areas reduces synaptic density and impairs long-term potentiation, the cellular correlate of memory formation [4].

The DIO2 Thr92Ala Polymorphism

Patients with two copies of the Thr92Ala variant appear to benefit more from combined T4/T3 therapy than from T4 alone. A 2009 analysis published in the European Journal of Endocrinology (N=141) found that homozygous Thr92Ala carriers reported significantly worse psychological well-being on levothyroxine monotherapy compared with heterozygotes or wild-type patients, and that adding T3 partially corrected this deficit [3]. Genetic testing for DIO2 is not yet standard of care, but it offers a plausible biological explanation for why some patients report persistent brain fog despite normal TSH on levothyroxine.

The Hoang et al. 2013 Trial: What It Actually Measured

Hoang et al. Conducted a 16-week, double-blind, randomized crossover study in 70 patients with primary hypothyroidism who were already stable on levothyroxine [5]. Each participant received either NDT or levothyroxine for one 8-week period, then crossed over to the other. The primary endpoint was a composite neurocognitive battery covering memory, attention, processing speed, and executive function.

Cognitive Scores: NDT vs. Levothyroxine

The composite neurocognitive score did not differ significantly between the NDT and levothyroxine arms [5]. Individual domain scores, including the Wechsler Memory Scale and Trail-Making Test, were likewise statistically equivalent. This is clinically meaningful: it rules out any large-magnitude cognitive harm from NDT, which was a concern given NDT's higher T3 content and its potential to cause supraphysiologic T3 spikes.

Patient-Reported Outcomes Tell a Different Story

Despite equivalent objective scores, 49% of participants preferred NDT at trial end, versus 19% who preferred levothyroxine and 23% who had no preference [5]. The most commonly cited reasons for preferring NDT were improved energy, better mood, and sharper mental clarity. The American Thyroid Association 2014 guidelines note this preference signal: "A trial of desiccated thyroid extract therapy could be offered to patients who have persistent symptoms on levothyroxine therapy, particularly if they express interest in trying a non-levothyroxine preparation." [6]

Weight Loss as a Surrogate Metabolic Signal

Participants on NDT lost a mean of 0.4 kg more than those on levothyroxine (P<0.05) [5]. While modest, this finding suggests slightly greater whole-body metabolic activity in the NDT arm, which may partially explain the subjective energy and mood improvement reported by participants.

Hypothyroidism and Cognitive Impairment: The Baseline Problem

Before attributing any cognitive gain to NDT specifically, it helps to understand how untreated or undertreated hypothyroidism damages cognition. Even subclinical hypothyroidism (TSH 4.5-10 mIU/L with normal free T4) is associated with reduced processing speed and working memory in adults under 65 [7].

Overt Hypothyroidism

Overt hypothyroidism (TSH >10 mIU/L) produces symptoms that can mimic early dementia: slowed thinking, poor concentration, depressed mood, and in severe cases myxedema coma [7]. Initiation of thyroid hormone replacement typically reverses these symptoms within 8-12 weeks, though some patients report residual cognitive complaints despite biochemically normal TSH on levothyroxine [8].

Residual Symptoms on Levothyroxine Monotherapy

A 2016 survey of 2,078 hypothyroid patients published in Thyroid found that patients on levothyroxine monotherapy reported significantly worse quality-of-life scores than age- and sex-matched euthyroid controls across seven of eight domains, including vitality and mental health [8]. This gap persisted even when TSH was within the 0.5-2.5 mIU/L target range. The residual burden is not trivial: approximately 15% of treated patients describe brain fog as their most disabling symptom.

How NDT Differs Pharmacokinetically from Levothyroxine

Armour Thyroid is derived from desiccated porcine thyroid gland. Each 60 mg grain contains approximately 38 mcg of T4 and 9 mcg of T3. The T3 component is absorbed rapidly, reaching peak serum concentration within 2-4 hours of ingestion, compared with T4's 2-4 day half-life [9].

T3 Peak and Its Clinical Implications

The rapid T3 peak after NDT ingestion can cause transient supraphysiologic free T3 levels, particularly in patients taking a single morning dose. This peaks at roughly 2-4 hours post-dose, then falls back toward baseline [9]. Symptoms during this window may include palpitations, anxiety, or a feeling of excessive stimulation. Splitting the daily NDT dose into two administrations (morning and early afternoon) blunts this peak and may reduce side effects without sacrificing efficacy.

TSH as a Monitoring Target: Caveats with NDT

Because NDT's T3 content suppresses TSH more per unit of thyroid hormone delivered than T4 alone, patients on NDT often show TSH values at or slightly below the lower reference limit even when they are not clinically hyperthyroid [10]. Clinicians should not reflexively reduce NDT dose based solely on a mildly suppressed TSH if the patient has no symptoms of thyrotoxicosis and free T3 remains within range. The Endocrine Society's 2012 clinical practice guideline recommends measuring both free T4 and free T3 in patients on combination therapy to avoid misclassification [10].

Evidence from Combined T4/T3 Therapy Trials

Armour Thyroid is not the only way to deliver T3. Several randomized trials have examined synthetic T4 plus synthetic T3 (liothyronine), and their cognitive findings inform how we interpret NDT data.

Bunevicius et al. 1999 (NEJM)

Bunevicius et al. Randomized 33 hypothyroid patients to levothyroxine alone or levothyroxine plus 12.5 mcg liothyronine (with a corresponding reduction in T4 dose) in a crossover design [11]. On the combination regimen, patients scored significantly better on 6 of 17 neuropsychological tests, including tests of attention and concentration. Mood also improved. This trial was small and has not been fully replicated, but it provided the first controlled human data that a T3 source contributes independently to cognitive outcomes.

Saravanan et al. 2006 (J Clin Endocrinol Metab)

Saravanan et al. (N=697 patients surveyed, with N=101 in a randomized component) found no significant difference in mood or cognition between combination T4/T3 and T4-alone groups at 12 months [12]. The discrepancy with Bunevicius et al. Likely reflects differences in patient selection, T3 dose, and trial duration. A 2019 meta-analysis in the Journal of Clinical Endocrinology and Metabolism pooling 15 randomized trials (N=1,216) concluded that combined T4/T3 therapy produced small but statistically significant improvements in mood and quality of life without a strong signal in objective cognitive test scores [13].

What This Means for NDT Specifically

NDT delivers the same two hormones as synthetic combination therapy, but in a fixed ratio derived from porcine anatomy rather than tailored to human physiology. The 4.22:1 T4:T3 ratio in NDT produces a higher relative T3 exposure than the human thyroid's approximate 14:1 secretion ratio [9]. This pharmacological difference means the cognitive (and cardiovascular) risk-benefit calculation for NDT requires individualized assessment.

A Clinical Decision Framework: Who May Benefit from NDT for Cognition

Not every patient with hypothyroidism and cognitive complaints will respond to NDT. The following patient profile, developed from the HealthRX clinical team's review of the primary literature, identifies characteristics that increase the likelihood of a meaningful cognitive response.

Patients More Likely to Benefit

• Persistent brain fog, memory difficulty, or low mood despite TSH in the 0.5-2.5 mIU/L range on levothyroxine for at least 6 months
• Free T3 consistently in the lower quartile of the reference range (e.g., <3.0 pg/mL on a 2.3-4.2 pg/mL reference) despite adequate T4
• History of total or near-total thyroidectomy, which eliminates residual endogenous T3 secretion from the gland
• Known or suspected DIO2 Thr92Ala polymorphism (confirmable via commercial genotyping)
• Patient preference for a non-synthetic preparation after informed discussion of evidence quality

Patients Who Should Not Use NDT

• Active cardiac arrhythmia or recent acute coronary syndrome (supraphysiologic T3 peaks increase arrhythmia risk)
• Osteoporosis without adequate antiresorptive therapy (excess thyroid hormone accelerates bone turnover)
• Pregnancy: NDT's fixed T4:T3 ratio is not recommended because fetal neural development requires consistent T4 delivery, and the T3 component does not cross the placenta efficiently [14]
• TSH already suppressed below 0.1 mIU/L on current therapy

Monitoring Protocol After Starting NDT

Check free T3, free T4, and TSH at 6-8 weeks after any dose initiation or change. Assess resting heart rate and ask specifically about palpitations, heat intolerance, and sleep disruption at each follow-up. If free T3 exceeds the upper reference limit or TSH falls below 0.1 mIU/L with symptoms, reduce dose by one half-grain (30 mg) and recheck in 6 weeks.

Practical Dosing: Converting from Levothyroxine to Armour Thyroid

Dose conversion is not perfectly linear because NDT contains T3. A commonly used starting conversion is 100 mcg levothyroxine ≈ 60 mg (1 grain) of Armour Thyroid, but individual variation is substantial [15]. Starting at 50-75% of the calculated equivalent dose and titrating upward reduces the risk of T3-mediated symptoms during transition.

Titration Schedule

Start NDT at approximately 30-45 mg daily if the patient was on 50-75 mcg levothyroxine, or 60 mg if converting from 100 mcg levothyroxine. Recheck labs at 6-8 weeks. Increase by 15-30 mg per titration step. Most patients reach their maintenance dose within 12-16 weeks [15].

Split Dosing to Reduce T3 Peaks

Taking NDT as a split dose (two-thirds in the morning, one-third 4-6 hours later) reduces the T3 peak-to-trough ratio. Patients who report palpitations or anxiety on single-dose NDT should try split dosing before switching back to levothyroxine. Small crossover pharmacokinetic studies suggest free T3 area-under-the-curve is similar between single and split dosing, so efficacy is preserved [9].

Safety Signals Relevant to Cognition

Excess thyroid hormone causes its own cognitive problems. Thyrotoxicosis produces anxiety, impaired concentration, and in older patients, a presentation that can mimic early cognitive decline [16]. NDT's higher T3 content makes iatrogenic thyrotoxicosis more likely than with levothyroxine if dosing is imprecise or monitoring is infrequent.

Bone Density

Suppressed TSH (below 0.1 mIU/L) for more than 12 months is associated with a 3-fold increase in hip fracture risk in women over 65, per a cohort study of 15,828 patients published in JAMA Internal Medicine [16]. Cognitive benefit does not offset skeletal harm; bone density monitoring (DXA scan at baseline and every 2 years) is appropriate in postmenopausal women and men over 70 starting NDT.

Cardiovascular Risk

A 2017 population-based cohort study (N=4,511) published in JAMA Internal Medicine found that exogenous thyroid hormone use with TSH <0.1 mIU/L was associated with a hazard ratio of 1.37 (95% CI 1.17-1.60) for atrial fibrillation compared with euthyroid controls [17]. Keeping TSH at or above 0.3 mIU/L on NDT substantially reduces this risk.

Regulatory and Supply Considerations

Armour Thyroid is FDA-regulated as a prescription drug under New Drug Application standards, distinguishing it from unregulated thyroid supplements sold over the counter. The FDA does not require bioequivalence studies between NDT lots in the same manner as for synthetic drugs, which has historically led to batch-to-batch variation in hormone content [18]. Patients who notice symptom recurrence without a dose change should ask their pharmacist to check whether a new lot number was dispensed.

Generic NDT products (NP Thyroid, Nature-Throid) may differ from Armour Thyroid in excipients and in quality control practices. Switching between NDT brands warrants a repeat TSH check at 6-8 weeks.